サンシャイン・バイオファーマ
Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -1.15 | $9M | -$912,847 |
| 2026 Q1 | -2.50 | $8M | -$2M |
| 2025 Q4 | -4.60 | $9M | -$845,762 |
| 2025 Q3 | -1.90 | $9M | -$761,943 |
| 2025 Q2 | -78.00 | $9M | -$2M |
| 2025 Q1 | -4.40 | $9M | -$2M |
| 2024 Q4 |
| -8.40 |
| $10M |
| -$4M |
| 2024 Q3 | -9.40 | $8M | -$2M |